Effect of Oral EGb761 on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-Blind, Parallel Groups, Placebo-Controlled Study.
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2016
At a glance
- Drugs EGb 761 (Primary)
- Indications Alzheimer's disease; Memory disorders
- Focus Therapeutic Use
- Sponsors Ipsen
- 29 Aug 2012 Planned end date changed from 1 Jul 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2012 Additional lead trial investigator (Helene Mathiex-Fortunet) identified as reported by ClinicalTrials.gov.